Valeant announces new leadership team roles

Valeant Pharmaceuticals International Inc. recently appointed of Paul S. Herendeen as the company’s new EVP of Finance.

Herendeen will also take over as Valeant’s CFO, replacing Robert L. Rosiello.

"Paul is an accomplished and well respected financial executive, and we are delighted to welcome him to Valeant," CEO Joseph Papa said. "His prior experience as a public company CFO, strong operational focus and disciplined approach to financial management make him the ideal choice to lead our finance function as we execute on our plans to stabilize and transform the company. As we move forward, Paul and the other members of the executive management team will play vital roles in shaping the new Valeant."

Rosiello has been named Valenat’s new EVP of Corporate Development and Strategy.

"I consider Rob Rosiello a trusted colleague," Papa said. "At a critical time, he led our team through a financial restatement, oversaw the process of becoming current in our SEC filings, and spearheaded our efforts to strengthen our finance team, particularly by recruiting a new chief accounting officer. Rob's integrity, work ethic and business acumen will be assets as we further develop our strategies to improve people's lives with our health care products."